Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States
Open Access
- 31 October 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 26 (1) , 1318-1329
Abstract
Out-of-pocket (OOP) costs may constitute a substantial financial burden to patients diagnosed with cancer. Earlier stage diagnosis and treatment of cancers may promote decreased morbidity and mortality, subsequently also lowering costs. To better understand costs experienced by patients with cancer, OOP costs by stage post-diagnosis were estimated. A retrospective analysis was conducted using Optum's de-identified Integrated Claims-Clinical dataset with Enriched Oncology, which includes data from commercially insured members (June 1, 2015-July 31, 2020). Mean annual and cumulative OOP costs (co-pay + co-insurance + deductible) (2020 USD) were reported through a 3-year period post-cancer diagnosis among adult commercially insured members (not including Medicare Advantage members) diagnosed with staged breast, cervical, colorectal, lung, ovarian, or prostate cancer between January 1, 2016 and June 30, 2020 with continuous enrollment for ≥1-month post-diagnosis. A total of 7,494 eligible members were identified who were diagnosed with breast, cervical, colorectal, lung, ovarian, or prostate cancer. A greater proportion of OOP costs were incurred in year 1 post-diagnosis but remained relatively high through year 3 post-diagnosis. Cumulative mean OOP costs were as high as $35,243 (lung stage IV) per commercially insured patient by year 3 post-diagnosis and were generally higher among those diagnosed at later stages (III/IV) than those diagnosed at earlier stages (I/II) across all cancers. Generalizability of these results is limited to those with commercial health insurance coverage. Additionally, cancer staging was dependent on accuracy of staging as recorded in the electronic medical record and as determined by Optum's proprietary algorithm using natural language processing. Cumulative mean OOP costs among commercially insured patients during the 3-year period post-cancer diagnosis were substantial and generally higher among those with later stage cancer diagnoses. Diagnosis of cancer at earlier stages may allow for more timely treatment and lessen patient OOP costs.Keywords
This publication has 27 references indexed in Scilit:
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal CancerJournal of Clinical Oncology, 2016
- The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast CancerJNCI: Journal of the National Cancer Institute, 2014
- Impact of Financial Burden of Cancer on Survivors' Quality of LifeJournal of Oncology Practice, 2014
- Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the ElderlyJournal of Managed Care Pharmacy, 2014
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2014
- Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care?Cancer, 2013
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer DiagnosisHealth Affairs, 2013
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's ExperienceThe Oncologist, 2013
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011